- Home
- CYD vs MREO Comparison
CYD vs MREO Comparison
Compare CYD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYD
- MREO
- Stock Information
- Founded
- CYD 1951
- MREO 2015
- Country
- CYD Singapore
- MREO United Kingdom
- Employees
- CYD N/A
- MREO N/A
- Industry
- CYD Industrial Machinery/Components
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CYD Industrials
- MREO Health Care
- Exchange
- CYD Nasdaq
- MREO Nasdaq
- Market Cap
- CYD 493.2M
- MREO 577.6M
- IPO Year
- CYD 1994
- MREO N/A
- Fundamental
- Price
- CYD $9.42
- MREO $3.68
- Analyst Decision
- CYD
- MREO Strong Buy
- Analyst Count
- CYD 0
- MREO 4
- Target Price
- CYD N/A
- MREO $7.50
- AVG Volume (30 Days)
- CYD 18.9K
- MREO 769.7K
- Earning Date
- CYD 08-12-2024
- MREO 11-12-2024
- Dividend Yield
- CYD 4.14%
- MREO N/A
- EPS Growth
- CYD 14.53
- MREO N/A
- EPS
- CYD 1.17
- MREO N/A
- Revenue
- CYD $2,639,608,357.00
- MREO $1,000,000.00
- Revenue This Year
- CYD $11.68
- MREO $16.39
- Revenue Next Year
- CYD $4.06
- MREO $9.44
- P/E Ratio
- CYD $7.82
- MREO N/A
- Revenue Growth
- CYD 15.32
- MREO N/A
- 52 Week Low
- CYD $7.85
- MREO $1.86
- 52 Week High
- CYD $13.05
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- CYD 28.75
- MREO 39.84
- Support Level
- CYD $8.91
- MREO $3.18
- Resistance Level
- CYD $9.55
- MREO $4.40
- Average True Range (ATR)
- CYD 0.45
- MREO 0.24
- MACD
- CYD -0.09
- MREO -0.06
- Stochastic Oscillator
- CYD 17.86
- MREO 41.39
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).